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Abstract The intracellular amyloid L-peptide (AL) binding
protein, ERAB, a member of the short-chain dehydrogenase/
reductase (SDR) family, is known to mediate apoptosis in
different cell lines and to be a class II hydroxyacyl-CoA
dehydrogenase. The AL peptide inhibits the enzymatic reaction
in a mixed type fashion with a Ki of 1.2 Wmol/l and a KiES of
0.3 Wmol/l, using 3-hydroxybutyryl-CoA. The peptide region
necessary for inhibition comprises residues 12^24 of AL1^40,
covering the 16^20 fragment, which is the minimum sequence for
the blockade of AL polymerization, but that minimal fragment is
not sufficient for more than marginal inhibition. The localization
of ERAB to the endoplasmic reticulum and mitochondria
suggests a complex interaction with components of the pro-
grammed cell death machinery. The interaction of AL with
ERAB further links oxidoreductase activity with both apoptosis
and amyloid toxicity.
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1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder a¡ecting cholinergic pathways in the brain. The hall-
marks of AD are extracellular senile plaques in the brain
parenchyma, amyloid depositions in the blood vessels and
intracellular neuro¢brillary tangles [1]. The major constituent
in plaques and amyloid depositions is the aggregated amyloid
L-peptide (AL), a proteolytic product of the amyloid precursor
protein (APP), whereas neuro¢brillary tangles are mainly
composed of hyperphosphorylated tau protein, derived from
microtubules [2]. APP is found in all human cells and increas-
ing evidence points to AL as a central e¡ector in the patho-
genesis of AD [3]. Underlying principles discussed in relation
to AL-mediated neuronal toxicity include, besides direct cyto-
toxicity, activation of proin£ammatory responses of the com-
plement system [4], production of reactive oxygen species
[5,6], increase of intracellular response to excitatory amino
acids, and disruption of calcium homeostasis [7].
An intracellular protein, identi¢ed with a two-hybrid assay
and termed ERAB, binds AL [8,9]. Upon binding AL, ERAB
mediates neurotoxicity and apoptosis in neuronal cell lines [8].
This protein has been identi¢ed as an enzyme and member of
the short-chain dehydrogenase/reductase (SDR) [10] super-
family, a protein family with currently over 1100 known struc-
tures [11]. Conserved sequence elements of this family include
a nucleotide cofactor binding site and an active center with a
Ser/Lys/Tyr triad [10]. ERAB has s 30% sequence identity to
its closest family members, prokaryotic 3-oxoacyl carrier pro-
tein reductases and hydroxysteroid dehydrogenases.
The aim of the present study was to investigate the inter-
action between AL and its intracellular target ERAB and to
study the e¡ect of the AL peptide on ERAB activity in the
search for functional links between oxidoreductive actions and
disease.
2. Materials and methods
2.1. ERAB cloning and expression of recombinant protein.
A human cDNA encoding ERAB was prepared with sequence-spe-
ci¢c primers by RT-PCR from poly(A) RNA (micro RNA prep,
Pharmacia) of a human liver sample obtained from a transplantation
donor. The resulting DNA was cloned into the expression plasmid
pET15b (Novagen) resulting in a recombinant protein with an N-
terminal poly-His tag and an integrated thrombin cleavage site, thus
enabling rapid puri¢cation by metal-chelate chromatography. The
construct was veri¢ed by DNA sequencing. After transformation
into Escherichia coli strain BL21, recombinant protein was expressed
by induction with 1 mM isopropylthiogalactoside. Cells were har-
vested 2 h after induction, lysed by sonication, and subjected to
Ni2-chelate chromatography (His-bind resin, Novagen). After wash-
ing, pure recombinant ERAB protein was eluted with 1 M imidazole,
150 mM NaCl in 20 mM Tris-HCl, pH 7.5. Immediately after puri-
¢cation, the protein was subjected to a bu¡er change by gel ¢ltration
(PD 10, Pharmacia), and dithiothreitol was added to a ¢nal concen-
tration of 10 mM to prevent precipitation. Protein concentrations
during puri¢cations were determined by the Lowry method, or in
the case of the pure protein by hydrolysis with 6 M HCl and amino
acid analysis with a ninhydrin-based instrument (Alpha Plus; Phar-
macia-LKB).
2.2. Subcellular fractionation.
Subcellular fractionation was performed by density gradient centri-
fugation [12]. The liver homogenate (10%, w/v) was prepared with a
Potter-Elvehjem homogenizer containing 0.25 M sucrose, 0.01 M
HEPES (pH 7.5), 0.1% ethanol and 1 mM dithiothreitol. The homo-
genate (4‡C) was centrifuged at 2000Ug for 15 min. The post-nuclear
supernatant was then subjected either to centrifugation at 35 000Ug
for 45 min to obtain a mitochondrial fraction, or to sucrose gradient
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centrifugation to obtain mitochondria, peroxisome- and ER-enriched
fractions. In the latter procedure, the post-nuclear supernatant was
layered on top of a pre-chilled 10^40% sucrose gradient and 65%
sucrose as a cushion, and subsequently subjected to centrifugation
at 100 000Ug for 16 h. Finally, fractions were collected from the
bottom of the tube. Organelle-speci¢c markers included catalase (per-
oxisomes), succinate dehydrogenase, cytochrome c (mitochondria),
glucose 6-phosphatase and 11L-hydroxysteroid dehydrogenase type 1
(endoplasmic reticulum, ER), detected by enzymatic analysis and
Western blotting.
2.3. Enzyme assays.
Analysis of enzyme activities was performed spectrophotometrically
by recording the change of absorbance of NAD at 340 nm, using a
molar extinction coe⁄cient of 6.22 M31 cm31 for NADH. One unit of
enzyme activity was de¢ned as 1 Wmol product formed per min at
25‡C. Dehydrogenase reactions were assayed in 50 mM Tris-HCl, pH
9.0, in the presence of 250 WM NAD, and reductase activities were
assayed in 50 mM Tris-HCl, pH 7.0, with 250 WM NADH. Kinetic
analysis was carried out with varying amounts of substrate (1^160
WM), and including 3-hydroxybutyryl-CoA, acetoacetyl-CoA (Sigma)
and the steroids (Sigma) testosterone (3-oxo-reductase, 17L-HSD ac-
tivities), isoursodeoxycholic acid (3L-HSD activity), cortisone (11-oxo-
reductase activity), cortisol (11L- and 20L-HSD activities) and andros-
terone (3K-HSD activity). Recombinant 3L/17L-hydroxysteroid dehy-
drogenase from Comamonas testosteroni was produced and puri¢ed as
described [13]. Type I hydroxyacyl-CoA dehydrogenase from pig
heart was purchased from Sigma. Inhibition experiments with AL
and its fragments were performed by preincubation of enzyme ali-
quots with di¡erent peptide concentrations for 30 min at 4‡C. Kinetic
data were collected and constants calculated using the Enzpack and
FigP for Windows software packages (Biosoft). Synthetic human
amyloid L-peptide 1^40 and fragments thereof were synthesized by
Fmoc chemistry with reagents obtained from Sigma. Synthesized pep-
tides were puri¢ed by RP-HPLC using an acetonitrile gradient in 0.1%
aqueous tri£uoroacetic acid, stored lyophilized at 320‡C until use,
and then redissolved in 20 mM Tris-HCl, pH 8.0. These peptide sol-
utions were stable and did not aggregate for at least 24 h. For all
inhibition experiments, only freshly prepared peptide solutions were
utilized.
2.4. Western blots
Protein samples (about 20 Wg per lane) were analyzed by SDS-
PAGE (12% or 10^20% polyacrylamide). After transfer to nitrocellu-
lose and blocking of unspeci¢c binding sites with 5% dry milk in
1UTBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween
20), the blots were incubated with primary antibodies for 2 h, fol-
lowed by washing in 1UTBST and incubation with secondary anti-
bodies for 2 h. After washing, visualization was achieved by chemo-
luminescence (ECL, Amersham). Primary antibodies employed were
polyclonal anti-ERAB, obtained from egg yolk by immunization of a
chicken with 100 Wg puri¢ed ERAB (secondary antibody: HRP-con-
jugated goat anti-chicken IgG; Sigma), polyclonal anti-11L-HSD-1
(mouse, secondary antibody goat-HRP-conjugated anti-rabbit IgG;
Amersham) and monoclonal anti-cytochrome c antibodies (PharmIn-
gen; secondary detection: HRP-conjugated protein A; Bio-Rad).
3. Results
Multiple sequence alignments revealed signi¢cant similar-
ities between ERAB, bacterial hydroxysteroid dehydrogenases
(about 40% identity) and vertebrate 3-hydroxyacyl-CoA dehy-
drogenases (about 80^90% identity) (Fig. 1), in agreement
with other SDR assignments [8,9,14]. Sequence identity within
Fig. 1. Multiple sequence alignment of SDR enzymes, showing the similarity between type II hydroxyacyl CoA dehydrogenases (human,
ERAB-hu; bovine, HACoADH-bo; and Drosophila melanogaster, HACoADH-DM), bacterial 3K/20L hydroxysteroid dehydrogenase (3K/20L-
HSD from Streptomyces hydrogenans), and 3L/17L-hydroxysteroid dehydrogenase (3L-HSD from Comamonas testosteroni). Identities between all
sequences are highlighted by black boxes, those between minimally three of the ¢ve sequences by gray boxes. Framed segments indicate the ac-
tive site and nucleotide binding motifs common to SDR enzymes. The ¢gure was created using the program PRALIN.
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the SDR family is otherwise 15^25%, and ERAB therefore
displays a surprisingly large positional identity to the bacterial
proteins, showing a clear evolutionary relationship. The sim-
ilarities to bovine and Drosophila type II hydroxyacyl-CoA
dehydrogenases [14] suggest that ERAB is the human ortho-
logue of these enzymes. We therefore performed a substrate
screening of the recombinant ERAB protein, including 3-OH-
acyl-CoAs, 3-ketoacyl-CoAs and steroids with hydroxy and
keto functions at positions C3, C11, C17 and C20, as given
in Section 2. Whereas no steroid dehydrogenase activities
could be detected with these substrates, recombinant human
ERAB catalyzed the reduction and oxidation of acetoacetyl-
CoA and 3-OH-butyryl-CoA (Km 22.7 Wmol/l, 1.1 U/mg; Km
65.7 Wmol/l, 9.8 U/mg, respectively). Thus, in agreement with
other studies reported during the course of this work [9,15], it
is fully established that ERAB is the human orthologue of the
type II hydroxyacyl-CoA dehydrogenase, as predicted [14].
Next, we investigated the e¡ect of AL binding on the enzy-
matic activity of ERAB. Preincubation of ERAB in the pres-
ence of AL1^40 and subsequent enzymatic assays revealed
inhibition of the ERAB 3-hydroxyacyl-CoA dehydrogenase
activity (Fig. 2A) in agreement with data from another study
[9]. Kinetic analysis indicated a mixed-type inhibition, with a
Ki of 1.2 Wmol/l and a KiES of 0.3 Wmol/l using 3-hydroxy-
butyryl-CoA as substrate. The speci¢city for 3-hydroxyacyl-
CoA dehydrogenase was evaluated by performing the same
sets of experiments with the structurally related bacterial 3L/
17L-HSD (Fig. 1) and the type I hydroxyacyl-CoA dehydro-
genase from pig heart mitochondria. No inhibition of the
reactions catalyzed by these enzymes could be observed with
AL1^40 (Fig. 2B,C), indicating that AL interacts speci¢cally
with ERAB.
We studied the e¡ects on ERAB activity by fragments of
AL in order to de¢ne the AL region that interacts with ERAB
(Fig. 3). Compared to full-length AL1^40 peptide, the region
necessary for inhibition of ERAB activity can be restricted to
the sequence 12^24, displaying 84% of the inhibition of the
full-length AL1^40 peptide under the conditions employed.
This segment is close to the minimal aggregate forming region
13^22 [16] of AL, and includes fragment 16^20 (KLVFF; Fig.
3), which is able to block polymerization [16], but that shorter
segment itself gives only marginal inhibition.
Subcellular fractionation of human liver samples using den-
sity gradient centrifugation was carried out to investigate the
intracellular distribution of ERAB (Fig. 4). Using di¡erent
markers for organelle speci¢city, ERAB could be detected
by Western blot analysis and enzymatic activity measurements
to reside in enriched mitochondrial and ER fractions, a ¢nd-
ing which is in accordance with immuno£uorescence data [8],
which describe ERAB as localized mainly to the ER. The
absence of ERAB-positive immunological signals in peroxiso-
mal fractions but a simultaneous presence of 3-hydroxyacyl-
CoA dehydrogenase activity in those fractions gives evidence
for the existence of enzymes structurally unrelated to ERAB
in peroxisomes.
4. Discussion
The fact that intracellular binding of AL to the ERAB
protein leads to apoptotic cell death has added a new dimen-
sion of L-amyloid-mediated e¡ects in Alzheimer’s disease [8].
In the present study, we aimed at de¢ning the subcellular
Fig. 2. Inhibition of enzyme activity by AL, showing the speci¢city
for ERAB (3-OH-acyl-CoA dehydrogenase). The enzymes (ERAB,
panel A, substrate 3-OH-butyryl-CoA; 3L/17L-HSD, panel B, 17L-
dehydrogenase, substrate testosterone; and type I hydroxyacyl-CoA
dehydrogenase from pig heart mitochondria, panel C, substrate
3-OH-butyryl-CoA) were preincubated in the absence (open circles)
or presence (open squares) of 0.5 WM AL1^40 and then assayed for
dehydrogenase activities. Strong inhibition of ERAB activity is ob-
served but no inhibition of the other enzymes is detected.
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distribution of ERAB, and the nature of the AL/ERAB inter-
action. From initial alignments (Fig. 1) and previous data
[8,14] we realized that ERAB was a SDR enzyme homologue
to vertebrate type II hydroxyacyl-CoA dehydrogenases. Dur-
ing the course of our substrate screening study, this was con-
¢rmed, and independently two reports recently suggested
ERAB to be identical to hydroxyacyl-CoA dehydrogenase
[9,15]. We evaluated possible e¡ects of AL binding on the
hydroxyacyl-CoA dehydrogenase activity, and demonstrated
an ER and mitochondrial distribution of ERAB, inhibition
of ERAB enzyme activity by AL, and a suggestion how these
events may be connected to the pathophysiology of neuro-
degenerative disorders and apoptotic processes.
Previous work has de¢ned the segment at positions 16^20
of the AL-peptide as the area essential for aggregation and
hence for ¢bril formation [16]. We now ¢nd that inhibition of
ERAB activity is optimal with the sequence 12^24 of AL, i.e.
an area covering the ¢bril-forming region 13^22, and over-
lapping the 16^20 segment, which iarea alone is insu⁄cient
for full inhibition but blocks ¢bril formation. It is intriguing
that AL toxicity (apoptosis or ¢bril formation) is critically
dependent on largely the same structural segment as the one
inhibiting the enzyme activity of ERAB. This interaction ap-
pears to be speci¢c for ERAB and AL, as demonstrated by the
lack of enzyme inhibition with the structurally or functionally
related enzymes 3L/17L-HSD and type I hydroxyacyl-CoA
dehydrogenase. From inspection of 3D structures homologous
to ERAB, the ER binding region cannot be deduced, whereas
the mitochondrial ERAB localization can be attributed to the
N-terminal sequence, possibly representing a non-cleavable
import signal [14]. Recent data reveal a wider substrate spe-
ci¢city for ERAB than just fatty acid CoA derivatives, includ-
ing aliphatic alcohols and estrogens [9]. In contrast, our data
and those of He et al. [15], did not reveal 17L-hydroxysteroid
dehydrogenase activity with other 17L-hydroxysteroids and at
present no clear mechanism linking AL-ERAB interactions
and apoptotic processes has been de¢ned. Although the
ERAB alcohol dehydrogenase activities could contribute di-
Fig. 3. Inhibition of ERAB hydroxyacyl-CoA dehydrogenase activity by di¡erent AL fragments. Inhibition of enzymatic activity was measured
in the presence of 0.5 WM peptide at substrate concentrations of 160 WM 3-OH-butyryl-CoA and 250 WM NAD. Values are given as percent
inhibition (number of experiments 3^7) compared to the uninhibited control reaction (no peptide).
Fig. 4. Subcellular localization of ERAB to mitochondria and ER in human liver. Human liver homogenate was separated by gradient centrifu-
gation, and fractions were analyzed for ERAB and organelle-speci¢c markers by immunological assays. Western blots using anti-ERAB, anti-
human cytochrome c and anti-11L-hydroxysteroid dehydrogenase antibodies, with total homogenate (H), enriched mitochondrial (M), peroxiso-
mal (P), and ER fractions.
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rectly to the lipid peroxidation products [9] this appears un-
likely since there are other, more e⁄cient cellular alcohol de-
hydrogenases. However, binding of AL to ERAB, occurring at
levels re£ecting intracellular AL concentrations [9], is not suf-
¢cient to promote cytotoxicity and cell death. Rather, func-
tional ERAB appears to be required for these e¡ects [9] and in
vitro inhibition relationships might not re£ect the in vivo sit-
uation.
Nevertheless, mediation of apoptosis by ERAB and AL
adds a new possible route to cell death, emphasizing the
role of mitochondria and oxidoreductases in this process
[17,18]. Another possible, hypothetical scenario, supported
by the localization of ERAB to ER and mitochondria, in-
cludes interruption of mitochondrial homeostasis or of energy
supply subsequently leading to the formation of reactive oxy-
gen species and release of apoptosis inducing factor and cy-
tochrome c. The cytotoxic activity of these molecules high-
lights the importance of the mitochondrion in programmed
cell death [19^24]. Since a similar segment of AL seems rele-
vant for two di¡erent postulated mechanisms of AL toxicity,
i.e. for ¢bril formation and for ERAB-mediated apoptosis,
pharmacological inhibition of one process may also a¡ect
the other.
Acknowledgements: This study was supported by grants from the
Swedish Medical Research Council (13X-3532, 4X-3766), the EC bio-
technology program (BIO 4 EC 97-2123), Novo Nordisk, and Kar-
olinska Institutet. S.S. is the recipient of a Wenner-Gren fellowship.
References
[1] Tomlinson, B.E. (1992) in: Green¢elds Neuropathology (Adams,
J.H. and Duchen, L.W., Eds.), pp. 1284^1410, Edward Arnold,
London.
[2] Mandelkow, E.M., Schweers, O., Drewes, G., Biernat, J.,
Gustke, N., Triczek, B. and Mandelkow, E. (1996) Ann. NY
Acad. Sci. 777, 96^106.
[3] Selkoe, D.J. (1996) J. Biol. Chem. 271, 18295^18298.
[4] Kalaria, R.N., Cohen, D.L. and Premkumar, D.R.D. (1996)
Neurodegeneration 5, 497^503.
[5] Simonian, N.A. and Coyle, J.T. (1996) Annu. Rev. Pharmacol.
Toxicol. 36, 83^106.
[6] Beal, M.F. (1996) Curr. Opin. Neurobiol. 6, 661^666.
[7] Mattson, M.P., Barger, S.W., Cheng, B., Lieberburg, I., Smith-
Swintosky, V.L. and Rydel, R.E. (1993) Trends Neurosci. 16,
409^414.
[8] Yan, S.D., Fu, J., Soto, C., Chen, X., Zhu, H., Al-Mohanna, F.,
Collison, K., Zhu, A., Stern, E., Saido, T., Tohyama, M., Oga-
wa, S., Roher, A. and Stern, D. (1997) Nature 389, 689^695.
[9] Yan, S.D., Shi, Y., Zhu, A., Fu, J., Zhu, H., Zhu, Y., Gibson, L.,
Stern, E., Collison, K., Al-Mohanna, F., Ogawa, S., Roher, A.,
Clarke, S. and Stern, D.M. (1999) J. Biol. Chem. 274, 2145^
2156.
[10] Jo«rnvall, H., Persson, B., Krook, M., Atrian, S., Gonzalez-
Duarte, R., Je¡ery, J. and Ghosh, D. (1995) Biochemistry 34,
6003^6013.
[11] Jo«rnvall, H., Ho«o«g, J.-O. and Persson, B. (1999) FEBS Lett. 445,
261^264.
[12] Whatmore, J., Morgan, C.P., Cunningham, E., Collison, K.S.,
Willison, K.R. and Cockcroft, S. (1996) Biochem. J. 320, 785^
794.
[13] Oppermann, U.C.T., Filling, C., Berndt, K.D., Persson, B., Be-
nach, J., Ladenstein, R. and Jo«rnvall, H. (1997) Biochemistry 36,
34^40.
[14] Furuta, S., Kobayashi, A., Miyazawa, S. and Hashimoto, T.
(1997) Biochim. Biophys. Acta 1350, 317^324.
[15] He, X.Y., Schulz, H. and Yang, S.Y. (1998) J. Biol. Chem. 273,
10741^10746.
[16] Tjernberg, L.O., Lillieho«o«k, C., Callaway, D.J.E., Na«slund, J.,
Hahne, S., Thyberg, J., Terenius, L. and Nordstedt, C. (1997)
J. Biol. Chem. 272, 12601^12605.
[17] Zhivotovsky, B., Handon, K.P., Hanson, K. and Orrenius, S.
(1998) Cell Death Di¡er. 5, 459^460.
[18] Bruschi, S.A., Lindsay, J.G. and Crabb, J.W. (1998) Proc. Natl.
Acad. Sci. USA 95, 13413^13418.
[19] Green, D.R. and Reed, J.C. (1998) Science 281, 1309^1312.
[20] Beal, M.F. (1996) Curr. Opin. Neurobiol. 6, 661^666.
[21] Mignotte, B. and Vayssiere, J.L. (1998) Eur. J. Biochem. 252, 1^
15.
[22] Choi, B.H. (1995) Neurobiol. Aging 16, 675^678.
[23] Beal, M.F., Hyman, B.T. and Koroshetz, W.J. (1993) Trends
Neurosci. 16, 125^131.
[24] Brouillet, E., Hantraye, P., Ferrante, R.J., Dolan, R., Leroy-Wil-
lig, A., Kowall, N.W. and Beal, M.F. (1992) Proc. Natl. Acad.
Sci. USA 92, 7105^7109.
FEBS 22046 25-5-99
U.C.T. Oppermann et al./FEBS Letters 451 (1999) 238^242242
